As filed with the Securities and Exchange Commission on October 31, 2024
Registration No. 333-

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________________________________

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
____________________________________________

Medifast, Inc.
(Exact name of registrant as specified in its charter)
____________________________________________

Delaware
(State or other jurisdiction of incorporation or organization)

13-3714405
(I.R.S. Employer Identification Number)
____________________________________________

100 International Drive
18th Floor
Baltimore, Maryland 21012
(Address of Principal Executive Offices)
____________________________________________

Medifast, Inc. Amended and Restated 2012 Share Incentive Plan
(Full title of the plan)
____________________________________________

Jason L. Groves, Esq.
Chief Legal Officer & Corporate Secretary
Medifast, Inc.
100 International Drive
18th Floor
Baltimore, Maryland 21012
Tel: (410) 581-8042

Copy to:

Bryan Brown, Esq.
Jones Day
717 Texas
Suite 3300
Houston, Texas 77002
Tel: (832) 239-3939
(Name, address and telephone number (including area code) of agent for service)
____________________________________________

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act (check one):


Large accelerated filer ☒

Non-accelerated filer ☐





Accelerated filer ☐

Smaller reporting company ☐

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐




EXPLANATORY NOTE

This Registration Statement is filed by Medifast, Inc., a Delaware corporation (the “Registrant”), pursuant to General Instruction E to Form S-8 to register an additional 515,000 shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), which may be awarded under the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (the “Plan”). On June 19, 2024, the Registrant’s stockholders approved the amendment and restatement of the Plan that increased by 515,000 the number of shares of Common Stock with respect to which the Registrant may make awards under the Plan.

The additional shares of Common Stock registered hereby pursuant to the Plan, as amended, are of the same class as other securities relating to the plan for which registration statements on Form S-8 (Nos. 333-218243 and 333-187974 are effective (the “Prior Registration Statements”)). The contents of the Prior Registration statements are incorporated herein by reference and made a part hereof except to the extent supplemented, amended or superseded by the information set forth herein.

PART I

INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

The information specified in Part I of Form S-8 is omitted from this registration statement in accordance with the provisions of Rule 428 under the Securities Act of 1933, as amended (the “Securities Act”), and the introductory note to Part I of Form S-8. The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants in the Plan, as required by Rule 428 promulgated by the Securities and Exchange Commission (the “Commission”) under the Securities Act. Such documents are not being filed with the Commission either as part of this registration statement or as prospectuses or prospectus supplements pursuant to Rule 424. These documents and the documents incorporated by reference in the registration statement shall constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 3. Incorporation of Documents by Reference.

The following documents previously filed by the Registration with the Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference:

aThe Registrants Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the SEC on February 20, 2024;

bThe Registrant’s Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024 and June 30, 2024, as filed with the SEC on April 29, 2024 and August 5, 2024, respectively;

cThe Registrant’s Current Report on Form 8-K, as filed with the SEC on June 21, 2024; and

dThe description of the Common Stock contained in Exhibit 4.1 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Commission on February 20, 2024, including any amendments or reports filed for the purpose of updating such description.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14, and 15(d) of the Exchange Act subsequent to the filing of this registration statement and prior to the filing of a post-effective amendment, which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference.



Any statement contained herein, or in a document incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained in any subsequently filed document that also is deemed to be incorporated by reference herein, modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

Item 4. Description of Securities.

Not applicable.

Item 5. Interests of Named Experts and Counsel.

Not applicable.

Item 6. Indemnification of Directors and Officers.

Section 102 of the Delaware General Corporation Law (the “DGCL”) permits a corporation to eliminate the personal liability of directors and officers of a corporation to the corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except (i) in cases where the director or officer breached his or her duty of loyalty to the corporation or its stockholders, failed to act in good faith, engaged in intentional misconduct or a knowing violation of the law, (ii) in cases where the director willfully or negligently authorized the unlawful payment of a dividend or approved an unlawful stock redemption or repurchase or obtained an improper personal benefit or, (iii) with respect to officers, in any action by or in the right of the Company. The Registrant’s Restated and Amended Certificate of Incorporation, as amended (the “Certificate of Incorporation”) and By-laws, (the “By-laws”), each contain a provision that eliminates directors’ personal liability as set forth above.

The Certificate of Incorporation and the By-laws provide in effect that the Registrant shall indemnify its directors and officers to the full extent permitted by the DGCL, Section 145 of the DGCL provides that a corporation has the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of such corporation or is or was serving at the request of such corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise. Such indemnification may include expenses (including attorneys’ fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, provided that such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person’s conduct was unlawful. A Delaware corporation is permitted to indemnify directors, officers, employees and other agents of such corporation in an action by or in the right of the corporation under the same conditions, except that no indemnification is permitted without judicial approval if the person to be indemnified has been adjudged to be liable to the corporation. Where a director, officer, employee or agent of the corporation is successful on the merits or otherwise in the defense of any action, suit or proceeding referred to above or in defense of any claim, issue or matter therein, the corporation must indemnify such person against the expenses (including attorneys’ fees) which he or she actually and reasonably incurred in connection therewith.

The Registrant maintains policies insuring its officers and directors against certain civil liabilities, including liabilities under the Securities Act.

Item 7. Exemption from Registration Claimed.

Not applicable.



Item 8. Exhibits.

Exhibit NumberDescription of Documents
4.1Medifast, Inc. Amended and Restated 2012 Share Incentive Plan (incorporated by reference from Exhibit 10.1 of the Registrant’s Current Report on Form 8-K filed with the Securities and Exchange Commission on June 21, 2024)
5.1
23.1
23.2
24.1
107
* Filed herewith.







SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Baltimore, State of Maryland, on October 31, 2024.

Medifast, Inc.


By:     /s/ DANIEL R. CHARD
Daniel R. Chard
Chairman & Chief Executive Officer


POWER OF ATTORNEY

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints, Daniel R. Chard and Jason L. Groves, Esq. and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and any registration statement relating to the offering covered by this Registration Statement and filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and to file the same, with exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated:

NameTitleDate
/s/ JEFFREY J. BROWNLead DirectorOctober 31, 2024
Jeffrey J. Brown
/s/ DANIEL R. CHARDChairman and Chief Executive OfficerOctober 31, 2024
Daniel R. Chard
/s/ ELIZABETH A. GEARYDirectorOctober 31, 2024
Elizabeth A. Geary
/s/ MICHAEL A. HOERDirectorOctober 31, 2024
Michael A. Hoer
/s/ JONATHAN B. MACKENZIEVice President Finance and Chief Accounting OfficerOctober 31, 2024
Jonathan B. MacKenzie
/s/ JAMES P. MALONEYChief Financial OfficerOctober 31, 2024
James P. Maloney
/s/ SCOTT SCHLACKMANDirectorOctober 31, 2024
Scott Schlackman
/s/ ANDREA B. THOMASDirectorOctober 31, 2024
Andrea B. Thomas
/s/ MING XIANDirectorOctober 31, 2024
Ming Xian


Medifast, Inc.0000910329S-8S-8EX-FILING FEESxbrli:sharesiso4217:USDxbrli:sharesiso4217:USDutr:Rate000091032912024-10-312024-10-3100009103292024-10-312024-10-31

Exhibit 107
Calculation of Filing Fee Tables
Medifast, Inc.
Table 1: Newly Registered Securities





Security TypeSecurity Class TitleFee Calculation RateAmount to be registered (1)Proposed Maximum Offering Price Per Unit ($)(2)Maximum Aggregate Offering Price ($)(2)Fee RateAmount of Registration Fee ($)
EquityCommon Stock, par value $0.001 per share457(h)515,000 17.749,136,100 0.000153101,398.74 
Total Offering Amounts9,136,100 1,398.74 
Total Fee Offsets0.00
Net Fee Due1,398.74 

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers such indeterminable number of additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), that become issuable under the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan, as amended and restated (the “Amended and Restated 2012 Plan”), by reason of any stock splits, stock dividends, recapitalization or similar transactions. The amount to be registered represents 515,000 additional shares of Common Stock that are available for grant under the Amended and Restated 2012 Plan, as amended and approved by the Registrant’s stockholders at its annual meeting on June 19, 2024.

(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The offering price per share and aggregate offering price are based upon the average of the high and low prices for the Common Stock as reported on the New York Stock Exchange on October 25, 2024, which date is within five business days prior to filing this Registration Statement in accordance with Rule 457(c) of the Securities Act.




Exhibit 5.1
Jones Day
717 Texas
Suite 3300
Houston, Texas 77002


October 31, 2024

Medifast, Inc.
100 International Drive
18th Floor
Baltimore, Maryland 21012

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have acted as counsel to Medifast, Inc. a Delaware corporation (the “Company”), in connection with the registration of an additional 515,000 shares (the “Additional 2012 Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”), that may be issued pursuant to the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan, as amended June 19, 2024 (the “2012 Plan”). In connection with the opinion expressed herein, we have examined such documents, records and matters of law as deemed relevant or necessary for purposes of such opinion. Based on the foregoing, and subject to the further limitations, qualifications and assumptions set forth herein, we are of the opinion that the Additional 2012 Shares that may be issued or delivered and sold pursuant to the 2012 Plan and authorized forms of stock option, restricted stock, restricted stock unit or other applicable agreements thereunder (the “Award Agreements”) will be, when issued or delivered and sold in accordance with such 2012 Plan and Award Agreements, validly issued, fully paid and nonassessable, provided that the consideration for the Additional 2012 Shares is at least equal to the stated par value thereof.

The opinion expressed herein is limited to the General Corporation Law of the State of Delaware, as currently in effect, and we express no opinion as to the effect of the laws of any other jurisdiction on the opinion expressed herein. In additional, we have assumed that the resolutions authorizing the Company to issue or deliver and sell the Additional 2012 Shares pursuant to the 2012 Plan and Award Agreements will be in full force and effect at all times at which such Additional 2012 Shares are issued or delivered or sold by the Company, and the Company will take no action inconsistent with such resolutions. In rendering the opinion above, we have assumed that each award under the 2012 Plan will be approved by the Board of Directors of the Company or an authorized committee thereof.

We hereby consent to the filing of this opinion as Exhibit 5.1 to the Registration Statement on Form S-8 filed by the Company to effect registration of the Shares under the Securities Act of 1933 (the “Act”). In giving such consent, we do not thereby admit that we are included in the category of persons whose consent is required under Section 7 of the Act or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.

Very truly yours,

/s/ Jones Day


Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in this Registration Statement on Form S-8 of Medifast, Inc. of our reports dated February 20, 2024, relating to the consolidated financial statements and the effectiveness of internal control over financial reporting of Medifast, Inc., appearing in the Annual Report on Form 10-K of Medifast, Inc. for the year ended December 31, 2023.

/s/ RSM US LLP

Baltimore, Maryland
October 31, 2024

v3.24.3
Submission
Oct. 31, 2024
Submission [Line Items]  
Central Index Key 0000910329
Registrant Name Medifast, Inc.
Form Type S-8
Submission Type S-8
Fee Exhibit Type EX-FILING FEES
v3.24.3
Offerings - Offering: 1
Oct. 31, 2024
USD ($)
shares
$ / shares
Rate
Offering:  
Fee Previously Paid false
Other Rule true
Security Type Equity
Security Class Title Common Stock, par value $0.001 per share
Amount Registered | shares 515,000
Proposed Maximum Offering Price per Unit | $ / shares 17.74
Maximum Aggregate Offering Price $ 9,136,100
Fee Rate | Rate 0.01531%
Amount of Registration Fee $ 1,398.74
Offering Note
(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the “Securities Act”), this Registration Statement also covers such indeterminable number of additional shares of the Registrant’s common stock, par value $0.001 per share (the “Common Stock”), that become issuable under the Medifast, Inc. Amended and Restated 2012 Share Incentive Plan, as amended and restated (the “Amended and Restated 2012 Plan”), by reason of any stock splits, stock dividends, recapitalization or similar transactions. The amount to be registered represents 515,000 additional shares of Common Stock that are available for grant under the Amended and Restated 2012 Plan, as amended and approved by the Registrant’s stockholders at its annual meeting on June 19, 2024.

(2) Estimated solely for the purpose of calculating the amount of the registration fee pursuant to Rule 457(h) of the Securities Act. The offering price per share and aggregate offering price are based upon the average of the high and low prices for the Common Stock as reported on the New York Stock Exchange on October 25, 2024, which date is within five business days prior to filing this Registration Statement in accordance with Rule 457(c) of the Securities Act.
v3.24.3
Fees Summary
Oct. 31, 2024
USD ($)
Fees Summary [Line Items]  
Total Offering $ 9,136,100
Total Fee Amount 1,398.74
Total Offset Amount 0.00
Net Fee $ 1,398.74
Grafico Azioni Medifast (NYSE:MED)
Storico
Da Ott 2024 a Nov 2024 Clicca qui per i Grafici di Medifast
Grafico Azioni Medifast (NYSE:MED)
Storico
Da Nov 2023 a Nov 2024 Clicca qui per i Grafici di Medifast